Skip to main content
Top
Published in: Virology Journal 1/2010

Open Access 01-12-2010 | Research

Distribution of hepatitis C virus genotypes among injecting drug users in Lebanon

Authors: Ziyad Mahfoud, Kassem Kassak, Khalil Kreidieh, Sarah Shamra, Sami Ramia

Published in: Virology Journal | Issue 1/2010

Login to get access

Abstract

Background

The aim of this study is to determine the prevalence of anti-HCV among injecting drug users (IDUs) in Lebanon, to establish the current prevalence of HCV genotypes in this population and to determine whether demographic characteristics and behavioral variables differ between participants who were HCV-RNA positive and those who were HCV-RNA negative or between the different genotypes. Participants were recruited using respondent-driven sampling method. The blood samples were collected as dried blood spots and then eluted to be tested for HCV, HBV and HIV by ELISA. Anti-HCV positive samples were subjected to RNA extraction followed by qualitative detection and genotyping.

Results

Among 106 IDUs, 56 (52.8%) were anti-HCV-positive. The two groups did not differ in terms of age, marital status, and nationality. As for the behavioral variable, there was a trend of increased risky behaviors among the HCV-RNA positive group as compared to the HCV-RNA negative group but none of the variables reached statistical significance. Half (50%) of the 56 anti-HCV-positive were HCV-RNA positive. Genotype 3 was the predominant one (57.1%) followed by genotype 1 (21%) and genotype 4 (18%).

Conclusions

The predominance of genotype 3 seems to be the predominant genotype among IDUs in Lebanon, a situation similar to that among IDUs in Western Europe. This study provides a base-line against possible future radical epidemiological variant that might occur in IDUs.
Literature
1.
go back to reference Lucidarme D, Decoster A, Fremaux D, Harbonnier J, Jacob C, Vosgien V, Josse P, Villeger P, Henrio C, Prouvost-Keller B, Saccardy C, Lemaire M, Vazeille G, Duchene C, Thuillier M, Colbeaux C, Lefebvre AM, Forzy G, Filoche B: Routine practice HCV infection screening with saliva samples: multicentric study in an intravenous drug user population. Gastroenterology and Clinical Biology 2007, 31: 480-484. 10.1016/S0399-8320(07)89415-2CrossRef Lucidarme D, Decoster A, Fremaux D, Harbonnier J, Jacob C, Vosgien V, Josse P, Villeger P, Henrio C, Prouvost-Keller B, Saccardy C, Lemaire M, Vazeille G, Duchene C, Thuillier M, Colbeaux C, Lefebvre AM, Forzy G, Filoche B: Routine practice HCV infection screening with saliva samples: multicentric study in an intravenous drug user population. Gastroenterology and Clinical Biology 2007, 31: 480-484. 10.1016/S0399-8320(07)89415-2CrossRef
2.
go back to reference Micalessi M, Gerard C, Ameye L, Plasschaert S, Brochier B, Vranckx R: Distribution of hepatitis C virus genotypes among injecting drug users in contract with treatment centers in Belgium 2004-2005. Journal of Medical Virology 2008, 80: 640-645. 10.1002/jmv.21145PubMedCrossRef Micalessi M, Gerard C, Ameye L, Plasschaert S, Brochier B, Vranckx R: Distribution of hepatitis C virus genotypes among injecting drug users in contract with treatment centers in Belgium 2004-2005. Journal of Medical Virology 2008, 80: 640-645. 10.1002/jmv.21145PubMedCrossRef
3.
go back to reference Pybus O, Cochrane A, Holmes E, Simmonds P: The hepatitis C virus epidemic among injecting drug users, Infection. Genetics and Evolution 2005, 5: 131-139. 10.1016/j.meegid.2004.08.001CrossRef Pybus O, Cochrane A, Holmes E, Simmonds P: The hepatitis C virus epidemic among injecting drug users, Infection. Genetics and Evolution 2005, 5: 131-139. 10.1016/j.meegid.2004.08.001CrossRef
4.
go back to reference Taylor A, Goldberg D, Hutchinson S, Cameron S, Gore SM, McMenamin J, Green S, Pithie A, Fox R: Prevalence of hepatitis C virus infection among injecting drug users in Glasgow 1990-1996: are current harm reduction strategies working? Journal of Infection 2000, 40: 176-183. 10.1053/jinf.2000.0647PubMedCrossRef Taylor A, Goldberg D, Hutchinson S, Cameron S, Gore SM, McMenamin J, Green S, Pithie A, Fox R: Prevalence of hepatitis C virus infection among injecting drug users in Glasgow 1990-1996: are current harm reduction strategies working? Journal of Infection 2000, 40: 176-183. 10.1053/jinf.2000.0647PubMedCrossRef
5.
go back to reference Goldberg D, Burns S, Taylor A, Cameron S, Hargreavas D, Hutchison S: Trends in HCV prevalence among injecting drug users in Glasgow and Edinburgh during the era of needle exchange. Scandinavian Journal Infectious Diseases 2001, 33: 457-461. 10.1080/00365540152029936CrossRef Goldberg D, Burns S, Taylor A, Cameron S, Hargreavas D, Hutchison S: Trends in HCV prevalence among injecting drug users in Glasgow and Edinburgh during the era of needle exchange. Scandinavian Journal Infectious Diseases 2001, 33: 457-461. 10.1080/00365540152029936CrossRef
6.
go back to reference de Lamballerie X, Charrel RN, Attoui H, De Miccop: Classification of hepatitis C virus variants in six major types based on analysis of the envelop 1 and non-structural 5B genome regions and complete polyprotein sequences. Journal of General Virology 1997, 78: 45-51.PubMedCrossRef de Lamballerie X, Charrel RN, Attoui H, De Miccop: Classification of hepatitis C virus variants in six major types based on analysis of the envelop 1 and non-structural 5B genome regions and complete polyprotein sequences. Journal of General Virology 1997, 78: 45-51.PubMedCrossRef
7.
go back to reference Tokita H, Okamoto H, Luengrojanakul P, Vareesangthip K, Chainuvati T, Iizuka H, Tsuda F, Miyakawa Y, Mayumi M: Hepatitis C virus variants from Thailand classifiable into five novel genotypes in the sixth (6b), seventh (7c, 7d) and ninth (9b, 9c) major genetic groups. Journal of General Virology 1995, 76: 2329-2335. 10.1099/0022-1317-76-9-2329PubMedCrossRef Tokita H, Okamoto H, Luengrojanakul P, Vareesangthip K, Chainuvati T, Iizuka H, Tsuda F, Miyakawa Y, Mayumi M: Hepatitis C virus variants from Thailand classifiable into five novel genotypes in the sixth (6b), seventh (7c, 7d) and ninth (9b, 9c) major genetic groups. Journal of General Virology 1995, 76: 2329-2335. 10.1099/0022-1317-76-9-2329PubMedCrossRef
8.
go back to reference Tokita H, Okamoto H, Iizuka H, Kishimoto J, Tsuda F, Lesmana LA, Miyakawa Y, Mayumi M: Hepatitis C virus variants from Jakarta, Indonesia, classifiable into novel genotypes in the second (2e and 2f), tenth (10a) and eleventh (11a) genetic groups. Journal of General Virology 1996, 77: 293-301. 10.1099/0022-1317-77-2-293PubMedCrossRef Tokita H, Okamoto H, Iizuka H, Kishimoto J, Tsuda F, Lesmana LA, Miyakawa Y, Mayumi M: Hepatitis C virus variants from Jakarta, Indonesia, classifiable into novel genotypes in the second (2e and 2f), tenth (10a) and eleventh (11a) genetic groups. Journal of General Virology 1996, 77: 293-301. 10.1099/0022-1317-77-2-293PubMedCrossRef
9.
go back to reference Simmonds P: Variability of the hepatitis C genome. In Hepatitis C virus. Edited by: Reesink HW. Karger, Basel; 1998. Simmonds P: Variability of the hepatitis C genome. In Hepatitis C virus. Edited by: Reesink HW. Karger, Basel; 1998.
10.
go back to reference Sharara A, Ramia S, Ramlawi F, Eid-Fares J, Klayme S, Naman R: Genotypes of hepatitis C virus (HCV) among positive Lebanese patients: comparison of data with that from other Middle Eastern countries. Epidemiology and Infection 2007, 135: 427-432. 10.1017/S0950268806006911PubMedPubMedCentralCrossRef Sharara A, Ramia S, Ramlawi F, Eid-Fares J, Klayme S, Naman R: Genotypes of hepatitis C virus (HCV) among positive Lebanese patients: comparison of data with that from other Middle Eastern countries. Epidemiology and Infection 2007, 135: 427-432. 10.1017/S0950268806006911PubMedPubMedCentralCrossRef
11.
go back to reference Kurbanov F, Tanaka Y, Sugauchi F, Kato H, Ruzibakiev R, Zalyalieva M, Yunusova Z, Mizokami M: Hepatitis C virus molecular epidemiology in Uzbekistan. Journal of Medical Virology 2003, 69: 367-375. 10.1002/jmv.10298PubMedCrossRef Kurbanov F, Tanaka Y, Sugauchi F, Kato H, Ruzibakiev R, Zalyalieva M, Yunusova Z, Mizokami M: Hepatitis C virus molecular epidemiology in Uzbekistan. Journal of Medical Virology 2003, 69: 367-375. 10.1002/jmv.10298PubMedCrossRef
12.
go back to reference Poynard T, Yuen MF, Ratziu V, Lai CL: Viral hepatitis C. Lancet 2004, 362: 2095-2100. 10.1016/S0140-6736(03)15109-4CrossRef Poynard T, Yuen MF, Ratziu V, Lai CL: Viral hepatitis C. Lancet 2004, 362: 2095-2100. 10.1016/S0140-6736(03)15109-4CrossRef
13.
go back to reference Pawlotsky JM, Tsakiris L, Roudot-Thoraval F, Pellet C, Stuyver L, Duval J, Dhumeaux D: Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. Journal of Infectious Diseases 1995, 171: 1607-1610.PubMedCrossRef Pawlotsky JM, Tsakiris L, Roudot-Thoraval F, Pellet C, Stuyver L, Duval J, Dhumeaux D: Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. Journal of Infectious Diseases 1995, 171: 1607-1610.PubMedCrossRef
14.
go back to reference Heckathorn DD: Respondent-driven sampling: A new approach to the study of hidden populations. Social Problems 1997, 44: 174-199. 10.1525/sp.1997.44.2.03x0221mCrossRef Heckathorn DD: Respondent-driven sampling: A new approach to the study of hidden populations. Social Problems 1997, 44: 174-199. 10.1525/sp.1997.44.2.03x0221mCrossRef
15.
go back to reference Parker SP, Gubilt WD: The use of the dried blood spot sample in epidemiological studies. J Clinical Pathology 1999, 52: 633-639. 10.1136/jcp.52.9.633CrossRef Parker SP, Gubilt WD: The use of the dried blood spot sample in epidemiological studies. J Clinical Pathology 1999, 52: 633-639. 10.1136/jcp.52.9.633CrossRef
16.
go back to reference Mathei C, Wollants E, Verbeeck J, Van Ranst M, Robaeys G, Van Damme P, Buntinx F: Molecular epidemiology of hepatitis C among drug users in Flanders, Belgium: association of genotypes with clinical parameters with sex and drug- related risk behaviors. European Journal Clinical Microbiology and Infectious Diseases 2005, 24: 514-522. 10.1007/s10096-005-1376-9CrossRef Mathei C, Wollants E, Verbeeck J, Van Ranst M, Robaeys G, Van Damme P, Buntinx F: Molecular epidemiology of hepatitis C among drug users in Flanders, Belgium: association of genotypes with clinical parameters with sex and drug- related risk behaviors. European Journal Clinical Microbiology and Infectious Diseases 2005, 24: 514-522. 10.1007/s10096-005-1376-9CrossRef
17.
go back to reference Lauer GM, Walker BD: Hepatitis C virus infection. New England Journal of Medicine 2001, 345: 41-52. 10.1056/NEJM200107053450107PubMedCrossRef Lauer GM, Walker BD: Hepatitis C virus infection. New England Journal of Medicine 2001, 345: 41-52. 10.1056/NEJM200107053450107PubMedCrossRef
18.
go back to reference Freeman AJ, Zekry A, Whybin LR, Harvey CE, van Beek IA, de Kantzow SL, Rawlinson WD, Boughton CR, Robertson PW, Marinos G, Lloyd AR: Hepatitis C prevalence among Australian injecting drug users in the 1970s and profiles of virus genotypes in the 1970s and 1990s. Medical Journal of Australia 2000, 172: 588-591.PubMed Freeman AJ, Zekry A, Whybin LR, Harvey CE, van Beek IA, de Kantzow SL, Rawlinson WD, Boughton CR, Robertson PW, Marinos G, Lloyd AR: Hepatitis C prevalence among Australian injecting drug users in the 1970s and profiles of virus genotypes in the 1970s and 1990s. Medical Journal of Australia 2000, 172: 588-591.PubMed
19.
go back to reference Mathei C, Buntinx F, Van Damme P: Is the prevalence of hepatitis C virus (HCV) RNA in an anti-HCV-positive injection drug users positively correlated with age? Journal of Infectious Diseases 2001, 184: 659-660. 10.1086/322795PubMedCrossRef Mathei C, Buntinx F, Van Damme P: Is the prevalence of hepatitis C virus (HCV) RNA in an anti-HCV-positive injection drug users positively correlated with age? Journal of Infectious Diseases 2001, 184: 659-660. 10.1086/322795PubMedCrossRef
20.
go back to reference Silini E, Bono F, Cividini A, Cerino A, Maccabruni A, Tinelli C, Bruno S, Bellobuono A, Mondelli M: Molecular epidemiology of hepatitis C virus infection among intravenous drug users. Journal of Hepatology 1995, 22: 691-695. 10.1016/0168-8278(95)80225-8PubMedCrossRef Silini E, Bono F, Cividini A, Cerino A, Maccabruni A, Tinelli C, Bruno S, Bellobuono A, Mondelli M: Molecular epidemiology of hepatitis C virus infection among intravenous drug users. Journal of Hepatology 1995, 22: 691-695. 10.1016/0168-8278(95)80225-8PubMedCrossRef
21.
go back to reference Zamani S, Ichikawa S, Nassirimanesh B, Vazirian M, Ichikawa K, Gouya MM, Afshar P, Ono-Kihara M, Ravari SM, Kihara M: Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. International Journal of Drug Policy 2007, 18: 359-563. 10.1016/j.drugpo.2007.02.007PubMedCrossRef Zamani S, Ichikawa S, Nassirimanesh B, Vazirian M, Ichikawa K, Gouya MM, Afshar P, Ono-Kihara M, Ravari SM, Kihara M: Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. International Journal of Drug Policy 2007, 18: 359-563. 10.1016/j.drugpo.2007.02.007PubMedCrossRef
22.
go back to reference Alzahrani AJ: Simultaneous detection of hepatitis C virus core antigen and antibodies in Saudi drug users using a novel assay. Journal of Medical Virology 2008, 80: 603-606. 10.1002/jmv.21075PubMedCrossRef Alzahrani AJ: Simultaneous detection of hepatitis C virus core antigen and antibodies in Saudi drug users using a novel assay. Journal of Medical Virology 2008, 80: 603-606. 10.1002/jmv.21075PubMedCrossRef
Metadata
Title
Distribution of hepatitis C virus genotypes among injecting drug users in Lebanon
Authors
Ziyad Mahfoud
Kassem Kassak
Khalil Kreidieh
Sarah Shamra
Sami Ramia
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2010
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-7-96

Other articles of this Issue 1/2010

Virology Journal 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine